Compound ID | 2991
Class: Beta-lactam
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against carbapenem-resistant Pseudomonas aeruginosa |
| Propensity to select resistant mutants: | Yes, at 9.3 x 10^-7 mutation frequency at 4xMIC |
| Description: | Synthetic compound; antibacterial activity is not affected by 𝛽-lactamases, efflux pumps, or outer membrane permeability changes; siderophore-conjugated monocarbam |
| Institute where first reported: | Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, USA |
| Year first mentioned: | 2010 |
| Development status: | Experimental |